A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
- MiNA Therapeutics Announces Enrolment of Patients in Expansion of Phase Ib Trial Evaluating MTL-CEBPA in Combination with Sorafenib on December 19, 2018 at 1:00 am
MiNA Therapeutics, the pioneer in RNA activation therapeutics ... We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. www.minatx ... […]
- Ramot and BioNTech Sign License Agreement to Use Novel Set of Lipids for Improved mRNA Delivery on December 19, 2018 at 12:28 am
(MENAFN - Newswire.com LLC) TEL AVIV, Israel, December 17, 2018 (Newswire.com) - Tel Aviv University (TAU) through Ramot, its Business Engagement Center, and BioNTech RNA Pharmaceuticals GmbH ... […]
- Injectable RNA Therapy Dramatically Improves Vision in Child Blindness on December 18, 2018 at 6:59 am
While Leber congenital amaurosis (LCA) may not have the name recognition of congenital disorders, it does represent one of the most common causes of blindness in children. Now, investigators at the Sc... […]
- Alternative RNA Splicing and Tumor Progression on December 17, 2018 at 11:02 am
Cancer Network: Normal alternative splicing allows cells to express multiple RNA and protein isoforms from a single gene ... splicing drivers may actually be linked to a mechanism of therapy resistanc... […]
- Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B on December 17, 2018 at 6:20 am
The goal of this therapy is to enable a patient's liver to produce a lifelong and stable supply of the clotting protein. Unlike conventional AAV cDNA gene therapy and lenti- or retroviral-based gene t... […]
- Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection on December 17, 2018 at 5:00 am
This Breakthrough Therapy designation is supported by data from Phase 2 clinical studies of lonafarnib-based treatment regimens in HDV-infected patients, achieving combined primary endpoints of ≥ 2 lo... […]
- Newly-Identified Human Protein Inhibits Replication of Ebola Virus on December 17, 2018 at 4:02 am
David Gladstone Institutes, Georgia State University and Northwestern University Feinberg School of Medicine has discovered a human protein that could one day lead to an effective therapy against ... ... […]
- Ionis Rising On RNA Therapy Optimism on December 14, 2018 at 3:52 pm
RNA therapies are a breakthrough category. Ionis leads the way with Biogen partnership for Spinraza. One new commercial drug plus an extensive pipeline point to a bright future. Ionis (IONS) is ... […]
- 2018 RNA Therapies in Oncology Analytical Tool - ResearchAndMarkets.com on December 13, 2018 at 10:04 am
This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your RNA therapy drug surveillance and intelligence, allowing you to power your decision making ... […]
via Bing News